AMT Medical, an Ede and Utrecht, the Netherlands-based clinical-stage medtech firm, raised $25M in Sequence B funding.
The spherical was led by Bender Analytical Holding B.V. (BAH). Different traders Make investments-NL, and the European Innovation Council (EIC) Oost NL and angels additionally participated.
The corporate intends to make use of the funds to help new key initiatives, together with CE marking and preliminary medical trials in america in open and robotic settings.
Led by CEO Rutger Tulleken, AMT Medical is a clinical-stage medtech firm spun out of neurovascular ELANA expertise which was earlier delivered to the market (CE and FDA). With 27 staff and ISO 13485-certification, it holds over 40 patents for its beating-heart surgical platform. The ELANA® Coronary heart Bypass System is a minimally invasive answer designed to switch conventional open-heart bypass surgical procedure, resulting in robot-assisted keyhole surgical procedure suitable with surgical robots.
Following this financing spherical, the capital will drive AMT’s working initiatives: Finishing AMT Medical’s European first-in-human trial evaluating the system throughout – nonetheless – open chest CABG procedures with a beating coronary heart.
FinSMEs
17/04/2025
